Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

Nature Medicine

Volumn 12, Issue 1, 2006, Pages 122-127

  Thomas, George V ^a   Tran, Chris ^a   Mellinghoff, Ingo K ^a   Welsbie, Derek S ^a   Chan, Emily ^a   Fueger, Barbara ^a   Czernin, Johannes ^a   Sawyers, Charles L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FLUORODEOXYGLUCOSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; TEMSIROLIMUS; TRACER; TUMOR SUPPRESSOR PROTEIN; VON HIPPEL LINDAU PROTEIN;

5' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; GENETIC CODE; GROWTH INHIBITION; IN VITRO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

5' UNTRANSLATED REGIONS; ANIMALS; ANOXIA; BRAIN; CELL LINE, TUMOR; DENSITOMETRY; DNA; DNA PRIMERS; DNA, COMPLEMENTARY; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOBLOTTING; KIDNEY NEOPLASMS; LUCIFERASES; MICE; NEOPLASM TRANSPLANTATION; POLYMERASE CHAIN REACTION; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BIOSYNTHESIS; PROTEIN KINASES; RADIOPHARMACEUTICALS; RNA, MESSENGER; TIME FACTORS; TRANSFECTION;

ANIMALIA; MAMMALIA;

EID: 30044432434     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1337     Document Type: Article

References (24)

1. Atkins, M.B. et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909-918 (2004).
2. Kim, W.Y. & Kaelin, W.G. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22, 4991-5004 (2004).
3. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, W.G., Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237-246 (2002).
4. Maranchie, J.K. et al. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247-255 (2002).
5. Hudson, C.C. et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22, 7004-7014 (2002).
6. Zhong, H. et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60, 1541-1545 (2000).
7. Laughner, E., Taghavi, P., Chiles, K., Mahon, P.C. & Semenza, G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21, 3995-4004 (2001).
8. Chen, F. et al. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res. 55, 4804-4807 (1995).
9. Iliopoulos, O., Ohh, M. & Kaelin, W.G., Jr. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc. Natl. Acad. Sci. USA 95, 11661-11666 (1998).
10. Mandriota, S.J. et al. HIF activation identifies early lesions in VHL kidneys. Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459-468 (2002).
11. Kaelin, W.G. Proline hydroxylation and gene expression. Annu. Rev. Biochem. 74, 115-128 (2005).
12. Guba, M. et al. Rapamycin inhibits primary and metastatic tumor growth by anti-angiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8, 128-135 (2002).
13. Arsham, A.M., Howell, J.J. & Simon, M.C. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J. Biol. Chem. 278, 29655-29660 (2003).
14. Aprelikova, O. et al. Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. J. Cell. Biochem. 92, 491-501 (2004).
15. Majumder, P.K. et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10, 594-601 (2004).
16. Hain, S.F. & Maisey, M.N. Positron emission tomography for urological tumours. BJU Int. 92, 159-164 (2003).
17. Joensuu, H. Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec). Med. Klin. (Munich) 97 Suppl. 1, 28-30 (2002).
18. Gayed, I. et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J. Nucl. Med. 45, 17-21 (2004).
19. Ferrara, N., Hillan, K.J., Gerber, H.P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400 (2004).
20. Blouw, B. et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4, 133-146 (2003).
21. Weinstein, I.B. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297, 63-64 (2002).
22. Rowinsky, E.K. Targeting the molecular target of rapamycin (mTOR). Curr. Opin. Oncol. 16, 564-575 (2004).
23. Chen, C.D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33-39 (2004).
24. Satyamurthy, N., Amarasekera, B., Alvord, C.W., Barrio, J.R. & Phelps, M.E. Tantalum [180]water target for the production of [18F]fluoride with high reactivity for the preparation of 2-deoxy-2-[18F]fluoro-D-glucose. Mol. Imaging Biol. 4, 65-70 (2002).